- Home
- FTK vs CRDF Comparison
FTK vs CRDF Comparison
Compare FTK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTK
- CRDF
- Stock Information
- Founded
- FTK 1985
- CRDF 1999
- Country
- FTK United States
- CRDF United States
- Employees
- FTK N/A
- CRDF N/A
- Industry
- FTK Major Chemicals
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FTK Industrials
- CRDF Health Care
- Exchange
- FTK Nasdaq
- CRDF Nasdaq
- Market Cap
- FTK 199.2M
- CRDF 185.6M
- IPO Year
- FTK N/A
- CRDF N/A
- Fundamental
- Price
- FTK $6.98
- CRDF $2.87
- Analyst Decision
- FTK Strong Buy
- CRDF Strong Buy
- Analyst Count
- FTK 2
- CRDF 4
- Target Price
- FTK $7.50
- CRDF $12.00
- AVG Volume (30 Days)
- FTK 167.2K
- CRDF 1.5M
- Earning Date
- FTK 05-06-2025
- CRDF 05-05-2025
- Dividend Yield
- FTK N/A
- CRDF N/A
- EPS Growth
- FTK N/A
- CRDF N/A
- EPS
- FTK 0.34
- CRDF N/A
- Revenue
- FTK $187,025,000.00
- CRDF $683,000.00
- Revenue This Year
- FTK $9.41
- CRDF N/A
- Revenue Next Year
- FTK $9.25
- CRDF N/A
- P/E Ratio
- FTK $20.56
- CRDF N/A
- Revenue Growth
- FTK N/A
- CRDF 39.96
- 52 Week Low
- FTK $3.13
- CRDF $2.01
- 52 Week High
- FTK $10.35
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- FTK 47.33
- CRDF 43.47
- Support Level
- FTK $6.40
- CRDF $2.81
- Resistance Level
- FTK $7.41
- CRDF $3.28
- Average True Range (ATR)
- FTK 0.45
- CRDF 0.25
- MACD
- FTK 0.08
- CRDF 0.06
- Stochastic Oscillator
- FTK 79.41
- CRDF 54.89
About FTK Flotek Industries Inc.
Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.